Dual antibody plus chemotherapy in metastatic colorectal cancer

Affiliations

Comment

Hiroyasu Yasuda et al. Immunotherapy. 2009 May.

. 2009 May;1(3):339-40.

¹ Department of Translational Research Center, Tohoku University, Sendai, Japan. yasuda@trc.med.tohoku.ac.jp

No abstract available

Comment on

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. Hecht JR, et al. J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29. J Clin Oncol. 2009. PMID: 19114685 Clinical Trial.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Tol J, et al. N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. N Engl J Med. 2009. PMID: 19196673 Clinical Trial.